M
Masashi Mizokami
Researcher at Nagoya City University
Publications - 684
Citations - 37168
Masashi Mizokami is an academic researcher from Nagoya City University. The author has contributed to research in topics: Hepatitis B virus & Hepatitis C virus. The author has an hindex of 85, co-authored 650 publications receiving 34868 citations. Previous affiliations of Masashi Mizokami include National Institute of Advanced Industrial Science and Technology & University of Florida.
Papers
More filters
Journal ArticleDOI
Association of serum IFN-λ3 with inflammatory and fibrosis markers in patients with chronic hepatitis C virus infection
Yoshihiko Aoki,Masaya Sugiyama,Kazumoto Murata,Sachiyo Yoshio,Masayuki Kurosaki,Satoru Hashimoto,Hiroshi Yatsuhashi,Hideyuki Nomura,Jong-Hon Kang,Tsutomu Takeda,Shigeko Naito,Tatsuji Kimura,Yoko Yamagiwa,Masaaki Korenaga,Masatoshi Imamura,Naohiko Masaki,Namiki Izumi,Masayoshi Kage,Masashi Mizokami,Tatsuya Kanto +19 more
TL;DR: Serum IFN-λ3 levels are increased in C-CH patients regardless of the IFNL3 genotype and is a biomarker reflecting the activity and fibrosis of liver disease, but is not correlated with the responsiveness to PEG-IFN-α plus RBV therapy.
Journal ArticleDOI
Nationwide prospective and retrospective surveys for hepatitis B virus reactivation during immunosuppressive therapies
Satoshi Mochida,Masamitsu Nakao,Nobuaki Nakayama,Yoshihito Uchida,Sumiko Nagoshi,Akio Ido,Toshihide Mimura,Masayoshi Harigai,Hiroshi Kaneko,Hiroko Kobayashi,Tetsuya Tsuchida,Hiromichi Suzuki,Nobuyuki Ura,Yuichi Nakamura,Masami Bessho,Kazuo Dan,Shigeru Kusumoto,Yasutsuna Sasaki,Hirofumi Fujii,Fumitaka Suzuki,Kenji Ikeda,Kazuhiko Yamamoto,Hajime Takikawa,Hirohito Tsubouchi,Masashi Mizokami +24 more
TL;DR: HBV reactivation during immunosuppression was responsible for liver injuries in a quarter of the ALF/LOHF patients with persistent HBV infection, and early serum HBV-DNA monitoring may improve patient prognosis.
Journal ArticleDOI
Application of a Glycoproteomics-Based Biomarker Development Method: Alteration in Glycan Structure on Colony Stimulating Factor 1 Receptor as a Possible Glycobiomarker Candidate for Evaluation of Liver Cirrhosis
Makoto Ocho,Akira Togayachi,Etsuko Iio,Hiroyuki Kaji,Atsushi Kuno,Maki Sogabe,Masaaki Korenaga,Masanori Gotoh,Yasuhito Tanaka,Yuzuru Ikehara,Masashi Mizokami,Hisashi Narimatsu +11 more
TL;DR: The results verified feasibility of this strategy for glycobiomarker development and established Wisteria floribunda agglutinin (WFA)-reactive CSF1R (W FA(+)-CSF 1R) as a novel possible glycobiOMarker candidate by utilizing a glycoproteomics-based strategy.
Journal ArticleDOI
Comparison of serum hepatitis C virus RNA concentration by branched DNA probe assay with competitive reverse transcription polymerase chain reaction as a predictor of response to interferon-α therapy in chronic hepatitis C patients
Hidenori Toyoda,Satoshi Nakano,Takashi Kumada,Isao Takeda,Keiichi Sugiyama,Toshimasa Osada,Seiki Kiriyama,Etsuro Orito,Masashi Mizokami +8 more
TL;DR: Measurement of serum HCV‐RNA concentration by bDNA probe assay was a better predictor of clinical response to IFNα therapy than measurement by cRT‐PCR.
Journal ArticleDOI
Slow evolutionary rate of GB virus C/hepatitis G virus.
Yoshiyuki Suzuki,Kazuhiko Katayama,Shuetsu Fukushi,Tsutomu Kageyama,A Oya,Hirofumi Okamura,Yasuhito Tanaka,Masashi Mizokami,Takashi Gojobori +8 more
TL;DR: The slow evolutionary rate for GBV-C/HGV suggested that this virus cannot escape from the immune response of the host by means of producing escape mutants, implying that it may have evolved other systems for persistent infection.